Clinical Trial Update: Gemcitabine-UFTE Chemotherapy in Refractory Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of Gemcitabine-UFTE chemotherapy in patients with metastatic or recurrent colorectal cancer refractory to standard agents has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Gemcitabine-UFTE (gemcitabine)

Snippet

Sponsor: Seoul National University Bundang Hospital | Conditions: Metastatic or Recurrent Colorectal Cancer, Refractory to Fluoropyrimidine, Oxaliplatin and Irinotecan | Phase 2 | Status: COMPLETED